Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review

Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review

Abstract Objectives This study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard care therapy (SCT) is cost-effective in heart failure with reduced ejection fraction (HFrEF). Method We searched r...

Full description

Bibliographic Details
Main Authors: Ghader Mohammadnezhad, Behniya Azadmehr, Mehdi Mirheidari, Nazila Yousefi
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Dapagliflozin
SGLT-2 inhibitors
Economic evaluation
Cost-effectiveness analysis
Heart failure
Online Access:https://doi.org/10.1186/s12962-022-00396-7

Internet

https://doi.org/10.1186/s12962-022-00396-7

Similar Items